• By ICR Secretariat
  • Posted Wednesday, January 15, 2020

GSK's plan to take over the HIV drug market hasn't worked out


British drug giant GlaxoSmithKline wants to claim a larger piece of the HIV drug market. Its strategy: convince patients, doctors and insurance providers that treatments made up of two drugs are better than those made up of three.